Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock
March 05, 2019 19:32 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an...
Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock
March 05, 2019 16:02 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2019 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2019,...
Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program
February 28, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route...
Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
February 27, 2019 16:05 ET
|
Sarepta Therapeutics, Inc.
RNA Franchise Advances-Reported EXONDYS 51® (eteplirsen) net sales of $84.4M for the quarter and full-year net sales of $301.0M, in line with guidance--Filed NDA for golodirsen with priority review,...
Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
February 27, 2019 09:00 ET
|
Sarepta Therapeutics, Inc.
-- In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially...
Sarepta Exercises Option to Acquire Myonexus Therapeutics
February 27, 2019 07:30 ET
|
Sarepta Therapeutics, Inc.
-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) -- CAMBRIDGE, Mass.,...
Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
February 20, 2019 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that commencing at 8:00 a.m....
Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
February 14, 2019 16:01 ET
|
Sarepta Therapeutics, Inc.
-- Trial to assess efficacy on neurodevelopmental status of MPS IIIA patients -- CAMBRIDGE, Mass. and PARIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering...
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
February 14, 2019 08:30 ET
|
Sarepta Therapeutics, Inc.
-- FDA Grants Priority Review Status -- -- Regulatory Action Date is August 19, 2019 -- -- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of...